In the ever-evolving landscape of healthcare, the use of Plaquenil (hydroxychloroquine) has garnered significant attention, particularly in relation to its potential impact on eye health. As we approach 2024, it's crucial to understand the updated guidelines for Plaquenil eye exams, ensuring the safety and well-being of patients undergoing this treatment.

The American Academy of Ophthalmology (AAO) has revised its guidelines to reflect the latest research and best practices. These updates, set to take effect in 2024, aim to minimize the risk of retinal toxicity associated with long-term Plaquenil use. Let's delve into the key aspects of these guidelines.

Plaquenil and Retinal Toxicity: Understanding the Risk
Plaquenil, a medication commonly used to treat malaria and certain autoimmune diseases like lupus and rheumatoid arthritis, can accumulate in the retina over time. This accumulation can lead to retinal toxicity, characterized by changes in visual fields, color vision, and visual acuity. The risk is typically associated with long-term use and high cumulative doses.

According to the AAO, the risk of retinal toxicity is approximately 7.5% after 5 years of use and 20% after 10 years. However, this risk can vary depending on individual factors, such as dosage, duration of use, and genetic predisposition.
Pre-Treatment Eye Exams: The New Norm

Starting in 2024, the AAO recommends that all patients initiating Plaquenil therapy undergo a comprehensive baseline eye exam. This exam should include a detailed medical history, best-corrected visual acuity, dilated fundus examination, and either spectral-domain optical coherence tomography (SD-OCT) or fundus autofluorescence (FAF) imaging.
This pre-treatment assessment will serve as a benchmark for future comparisons, enabling healthcare providers to monitor any changes in retinal health over time. It's crucial to note that patients should be informed about the potential risks and the importance of regular eye exams during Plaquenil therapy.
Frequency of Follow-Up Eye Exams

The AAO suggests that patients on Plaquenil therapy should have follow-up eye exams every 6 months for the first year, then annually thereafter. These exams should include a detailed medical history, best-corrected visual acuity, dilated fundus examination, and SD-OCT or FAF imaging.
However, the frequency of these exams may vary depending on individual risk factors. For instance, patients with a cumulative dose of Plaquenil greater than 1000 grams, those with pre-existing retinal disease, or those with a family history of retinal toxicity may require more frequent monitoring.
Managing Retinal Toxicity: Early Detection and Intervention

Early detection of retinal toxicity is crucial for preventing permanent vision loss. The AAO emphasizes the importance of prompt intervention if any signs of toxicity are detected during routine eye exams.
Management strategies may include dose reduction, discontinuation of Plaquenil, or switching to an alternative medication. In some cases, patients may require referral to a retina specialist for further evaluation and management.



















Genetic Testing: A New Tool in Risk Assessment
Recent advancements in genetic testing have provided a new tool for assessing an individual's risk of Plaquenil-induced retinal toxicity. The AAO recommends considering genetic testing in patients at high risk, such as those with a family history of retinal toxicity or those with certain genetic variants associated with increased risk.
However, it's essential to note that genetic testing is not yet widely available or standardized. As such, its role in clinical decision-making is still evolving and should be considered on a case-by-case basis.
As we look ahead to 2024, the updated Plaquenil eye exam guidelines emphasize the importance of proactive management and regular monitoring. By staying informed and adhering to these guidelines, healthcare providers can help ensure the safety and visual health of patients undergoing Plaquenil therapy. It's a reminder that, in the realm of healthcare, vigilance and timely intervention are key to preserving our most precious sense - sight.